# GSK receives FDA fast track designation for Bepirovirsen for Chronic Hepatitis B

- Link: https://www.directorstalkinterviews.com/gsk-receives-fda-fast-track-designation-for-bepirovirsen-for-chronic-hepatitis-b/4121142243
- Published: 2024-02-12T07:43:10+00:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE: GSK) has announced that the US Food and Drug Administration (FDA) has 
granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide(
ASO) for the treatment of chronic hepatitis B (CHB). Fast track designation is intended
to facilitate the development and expedite the review of drugs to treat serious 
conditions and fill an unmet medical need.

·   Designation underscores the unmet need for medicines that can achieve functional
cure in patients with chronic hepatitis B (CHB)

The designation was requested based on the potential for bepirovirsen to address
an unmet medical need for CHB, a serious and life-threatening condition. Data from
the phase IIb trials B-Clear and B-Sure, which evaluated the efficacy, safety and
durability of response of bepirovirsen in people with CHB, were submitted in support
of the application. A confirmatory phase III programme, B-Well, is ongoing.

CHB affects nearly 300 million people worldwide,^(1) and current treatment options
offer a less than 2-8% functional cure rate which is not clinically meaningful.^(
2) Functional cure occurs when the hepatitis B virus DNA and viral proteins are 
at levels low enough to be undetectable in the blood and can be controlled by the
immune system without medication. Currently available oral antiviral therapies –
called nucleoside/nucleotide analogues (NAs) – only suppress the virus and do not
directly lower hepatitis B surface antigen (HBsAg), which is essential for functional
cure.

Bepirovirsen is the only single agent in phase III development that has shown the
potential to achieve clinically meaningful functional cure response when combined
with oral nucleoside/nucleotide analogues (NAs). This was demonstrated by positive
results in the B-Clear and B-Sure clinical trials.^(3,4) B-Clear identified that
patients with low baseline hepatitis B surface antigen levels are most likely to
benefit from treatment with bepirovirsen. Bepirovirsen is also being investigated
as a potential backbone therapy in future sequential regimens to pursue functional
cure in a broader population of patients with CHB.

**References**

1 World Health Organisation. Hepatitis B Key Facts, January 2023 

2 Slaets L, et al. Systematic review with meta-analysis: hepatitis B surface antigen
decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues
or pegylated interferon therapy. GastroHep. 2020;2(3):106-116.

3 Yuen M-F, Lim S-G, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic
hepatitis B infection. N Engl J Med. 2022;387(21):1957-68.

4 Gadano et al. EASL 2023 Abstract 4132

Share on:
